A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation

Artemov, A.; Aliper, A.; Korzinkin, M.; Lezhnina, K.; Jellen, L.; Zhukov, N.; Roumiantsev, S.; Gaifullin, N.; Zhavoronkov, A.; Borisov, N.; Buzdin, A.

Авторы: Artem Artemov, Alexander Aliper, Michael Korzinkin, Ksenia Lezhnina, Leslie Jellen, Nikolay Zhukov, Sergey Roumiantsev, Nurshat Gaifullin, Alex Zhavoronkov, Nicolas Borisov, Anton Buzdin
Журнал: Oncotarget
Том: 30
Номер: 6
Год издания: 2015
Издательство: Impact Journals
Местоположение издательства: Albany, N.Y., United States
Первая страница: 29347
Последняя страница: 29356
Аннотация: A new generation of anticancer therapeutics called target drugs has quickly developed in the 21st century. These drugs are tailored to inhibit cancer cell growth, proliferation, and viability by specific interactions with one or a few target proteins. However, despite formally known molecular targets for every “target” drug, patient response to treatment remains largely individual and unpredictable. Choosing the most effective personalized treatment remains a major challenge in oncology and is still largely trial and error. Here we present a novel approach for predicting target drug efficacy based on the gene expression signature of the individual tumor sample(s). The enclosed bioinformatic algorithm detects activation of intracellular regulatory pathways in the tumor in comparison to the corresponding normal tissues. According to the nature of the molecular targets of a drug, it predicts whether the drug can prevent cancer growth and survival in each individual case by blocking the abnormally activated tumor-promoting pathways or by reinforcing internal tumor suppressor cascades. To validate the method, we compared the distribution of predicted drug efficacy scores for five drugs (Sorafenib, Bevacizumab, Cetuximab, Sorafenib, Imatinib, Sunitinib) and seven cancer types (Clear Cell Renal Cell Carcinoma, Colon cancer, Lung adenocarcinoma, non-Hodgkin Lymphoma, Thyroid cancer and Sarcoma) with the available clinical trials data for the respective cancer types and drugs. The percent of responders to a drug treatment correlated significantly (Pearson’s correlation 0.77 p = 0.023) with the percent of tumors showing high drug scores calculated with the current algorithm.
Добавил в систему: Гайфуллин Нуршат Минуллаевич

	ИСТИНА	Войти в систему Регистрация
	Интеллектуальная Система Тематического Исследования НАукометрических данных
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

Интеллектуальная Система Тематического Исследования НАукометрических данных

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activationстатья

Прикрепленные файлы